Woo Sun Rou1, Byung Seok Lee1, Hee Seok Moon1, Eaum Seok Lee1, Seok Hyun Kim1, Heon Young Lee1. 1. Woo Sun Rou, Byung Seok Lee, Hee Seok Moon, Eaum Seok Lee, Seok Hyun Kim, Heon Young Lee, Division of Gastroenterology, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon 301-721, South Korea.
Abstract
AIM: To identify factors affecting early local recurrence after transcatheter arterial chemoembolization (TACE) and investigate treatments and outcomes for local recurrence. METHODS: Early local recurrence and no early local recurrence groups drawn from 134 patients who were initially diagnosed with hepatocellular carcinoma (HCC) and showed a complete response (CR) to TACE treatment between January 1, 2006, and January 31, 2012, were analyzed by univariate and multivariate analyses. Additionally, the subsequent treatment for patients with recurrence was analyzed, and in cases in which TACE had been performed, the cumulative recurrence rates were calculated using the Kaplan-Meier method and compared with those of the primary lesion. RESULTS: The 1-, 2-, and 3-year survival rates were 92.3%, 60.2%, and 39.8%, respectively, in the early local recurrence group, which were significantly lower than those in both the late local and no local recurrence groups (P < 0.001). On multivariate analyses, non-compact lipiodol uptake, large tumor size, and an alpha-fetoprotein > 20 ng/mL after achieving a CR were significant predictors. When TACE was performed for early and late locally recurrent lesions, a CR was observed in 15 patients (41.7%) and 11 patients (78.6%), and the cumulative recurrence rates at 6, 12, and 24 mo were 17.9%, 43.3%, and 71.2%, respectively, which did not differ significantly from those after the first CR of 20.5%, 44.0%, and 58.6%, respectively (P = 0.639). CONCLUSION: Closer monitoring and active treatments must be provided to patients with risk factors for early local recurrence of HCC.
AIM: To identify factors affecting early local recurrence after transcatheter arterial chemoembolization (TACE) and investigate treatments and outcomes for local recurrence. METHODS: Early local recurrence and no early local recurrence groups drawn from 134 patients who were initially diagnosed with hepatocellular carcinoma (HCC) and showed a complete response (CR) to TACE treatment between January 1, 2006, and January 31, 2012, were analyzed by univariate and multivariate analyses. Additionally, the subsequent treatment for patients with recurrence was analyzed, and in cases in which TACE had been performed, the cumulative recurrence rates were calculated using the Kaplan-Meier method and compared with those of the primary lesion. RESULTS: The 1-, 2-, and 3-year survival rates were 92.3%, 60.2%, and 39.8%, respectively, in the early local recurrence group, which were significantly lower than those in both the late local and no local recurrence groups (P < 0.001). On multivariate analyses, non-compact lipiodol uptake, large tumor size, and an alpha-fetoprotein > 20 ng/mL after achieving a CR were significant predictors. When TACE was performed for early and late locally recurrent lesions, a CR was observed in 15 patients (41.7%) and 11 patients (78.6%), and the cumulative recurrence rates at 6, 12, and 24 mo were 17.9%, 43.3%, and 71.2%, respectively, which did not differ significantly from those after the first CR of 20.5%, 44.0%, and 58.6%, respectively (P = 0.639). CONCLUSION: Closer monitoring and active treatments must be provided to patients with risk factors for early local recurrence of HCC.
Authors: Y Sasaki; S Imaoka; H Kasugai; M Fujita; S Kawamoto; S Ishiguro; J Kojima; O Ishikawa; H Ohigashi; H Furukawa Journal: Cancer Date: 1987-09-15 Impact factor: 6.860
Authors: K Takayasu; Y Shima; Y Muramatsu; N Moriyama; T Yamada; M Makuuchi; H Hasegawa; S Hirohashi Journal: Radiology Date: 1987-05 Impact factor: 11.105
Authors: Sang Hoon Jeon; Kyung Sik Park; Young Hwan Kim; Yo Sig Shin; Min Kyoung Kang; Byoung Kuk Jang; Woo Jin Chung; Kwang Bum Cho; Jae Seok Hwang Journal: Korean J Gastroenterol Date: 2007-09
Authors: G F Stefanini; P Amorati; M Biselli; F Mucci; A Celi; V Arienti; R Roversi; C Rossi; G Re; G Gasbarrini Journal: Cancer Date: 1995-05-15 Impact factor: 6.860
Authors: Jun Qian; Elsie Oppermann; Andreas Tran; Ulli Imlau; Kun Qian; Thomas Josef Vogl Journal: World J Gastroenterol Date: 2016-06-07 Impact factor: 5.742
Authors: Crisanta H Ilagan; Debra A Goldman; Mithat Gönen; Victoria G Aveson; Michelle Babicky; Vinod P Balachandran; Jeffrey A Drebin; William R Jarnagin; Alice C Wei; T Peter Kingham; Ghassan K Abou-Alfa; Karen T Brown; Michael I D'Angelica Journal: Ann Surg Oncol Date: 2022-07-15 Impact factor: 4.339
Authors: Shin Ok Jeong; Eui Bae Kim; Soung Won Jeong; Jae Young Jang; Sae Hwan Lee; Sang Gyune Kim; Sang Woo Cha; Young Seok Kim; Young Deok Cho; Hong Soo Kim; Boo Sung Kim; Yong Jae Kim; Dong Erk Goo; Su Yeon Park Journal: Gut Liver Date: 2017-05-15 Impact factor: 4.519